Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IFB-088 in Healthy Volunteers
NCT03610334Phase 1Completed
- Sponsor
- InFlectis BioScience
- Start
- Jun 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Icerguastat in Charcot-Marie-Tooth disease (CMT) and amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by InFlectis BioScience. Primary endpoint: Treatment Emergent Adverse Events. Started Jun 2018; status: completed.
02
Drugs
Icerguastat
03
Conditions
Charcot-Marie-Tooth disease (CMT)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03610334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610334.